Preventive medicine company Endless Health has secured $4.5 million in seed funding to expand its at-home blood test powered service into longevity. The Texas-based company aims to build on its established cardiovascular health offering by expanding its testing panels to include Alzheimer’s disease and other chronic conditions.

The new funding will be used to develop Endless Health’s at-home clinical trial services, including self-collection kits and central lab services. Its services will focus on tracking key longevity blood markers, with its first clinical trials for at-home and point-of-care medical devices expected to conclude by the end of this summer.

With the new funds, Endless Health plans to scale its white-label testing services to millions of people, leveraging at-home testing capabilities to conduct clinical trials more cost-effectively and efficiently.

The round was led by Next Coast Ventures, with participation of TA Ventures, Asset Management Ventures and Antler Elevate.